deferoxamine has been researched along with Mucormycosis in 42 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Mucormycosis: Infection in humans and animals caused by any fungus in the order MUCORALES (e.g., RHIZOPUS; MUCOR; CUNNINGHAMELLA; APOPHYSOMYCES; ABSIDIA; SAKSENAEA and RHIZOMUCOR) There are many clinical types associated with infection including central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an OPPORTUNISTIC INFECTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigates the pathophysiology of mucormycosis caused by Rhizopus, which has been reported in 46 dialysis patients, while treated with deferoxamine (DFO)." | 7.68 | Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. ( Boelaert, JR; Cantinieaux, B; de Locht, M; Kerrels, V; Schneider, YJ; Van Cutsem, J; Van Landuyt, HW; Verdonck, A, 1993) |
| "Two maintenance hemodialysis patients receiving deferoxamine to chelate iron and aluminum developed intestinal mucormycosis." | 7.67 | Intestinal mucormycosis in hemodialysis patients following deferoxamine. ( Eiser, AR; Neff, MS; Slifkin, RF, 1987) |
| "Mucormycosis was induced in healthy guinea pigs by the i." | 5.28 | Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). ( Boelaert, JR; Van Cutsem, J, 1989) |
| "Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis." | 5.28 | [A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989) |
| "The increased risk of mucormycosis in patients with renal failure receiving deferoxamine iron chelation therapy is explained by the fact that deferoxamine actually acts as a siderophore for the agents of mucormycosis, supplying previously unavailable iron to the fungi." | 4.84 | Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. ( Edwards, J; Ibrahim, AS; Spellberg, B, 2008) |
| " In July 1996, deferoxamine was administered for iron overload." | 4.80 | [Development of arterial thrombus of Mucorales hyphae during deferoxamine therapy in a patient with aplastic anemia in transformation to myelodysplastic syndrome]. ( Kajiguchi, T; Miyata, Y; Saito, M; Takeyama, H, 2000) |
| "A case of fatal intestinal mucormycosis in a 57-year-old female hemodialysis patient who had received desferrioxamine (DFO) for aluminum overload is reported." | 4.78 | Intestinal mucormycosis in a hemodialysis patient treated with desferrioxamine. ( Abe, F; Hotchi, M; Ito, M; Kaneko, T; Okada, Y; Yamada, K, 1991) |
| "Dialysis patients with chronic renal failure receiving deferoxamine for treating iron overload are uniquely predisposed for mucormycosis, which is most often caused by Rhizopus oryzae." | 3.81 | Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine. ( Chou, TF; Edwards, JE; French, SW; Gebremariam, T; Ibrahim, AS; Lin, L; Liu, M; Luo, G; Skory, CD, 2015) |
| "Deferoxamine (DFO), when used in dialysis patients, is a well recognized risk factor for the development of mucormycosis caused by Rhizopus." | 3.69 | Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. ( Boelaert, JR; Crichton, RR; de Locht, M; Schneider, YJ; Van Cutsem, J, 1994) |
| "This study investigates the pathophysiology of mucormycosis caused by Rhizopus, which has been reported in 46 dialysis patients, while treated with deferoxamine (DFO)." | 3.68 | Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. ( Boelaert, JR; Cantinieaux, B; de Locht, M; Kerrels, V; Schneider, YJ; Van Cutsem, J; Van Landuyt, HW; Verdonck, A, 1993) |
| "Two maintenance hemodialysis patients receiving deferoxamine to chelate iron and aluminum developed intestinal mucormycosis." | 3.67 | Intestinal mucormycosis in hemodialysis patients following deferoxamine. ( Eiser, AR; Neff, MS; Slifkin, RF, 1987) |
| " The interdialytic half-life of ferrioxamine was 2." | 2.67 | Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ( Becaus, I; Boelaert, JR; D'Haese, PC; De Broe, ME; Lamberts, LV; Verpooten, GA, 1992) |
| "Mucormycosis was the primary cause of death in three of the five patients." | 1.30 | Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. ( Boogaerts, MA; Demuynck, H; Maertens, J; Vandenberghe, P; Verbeken, EK; Verhoef, GE; Zachée, P, 1999) |
| "Mucormycosis was induced in healthy guinea pigs by the i." | 1.28 | Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). ( Boelaert, JR; Van Cutsem, J, 1989) |
| "Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis." | 1.28 | [A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (35.71) | 18.7374 |
| 1990's | 19 (45.24) | 18.2507 |
| 2000's | 7 (16.67) | 29.6817 |
| 2010's | 1 (2.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M | 1 |
| Lin, L | 1 |
| Gebremariam, T | 1 |
| Luo, G | 1 |
| Skory, CD | 1 |
| French, SW | 1 |
| Chou, TF | 1 |
| Edwards, JE | 1 |
| Ibrahim, AS | 2 |
| Spellberg, B | 1 |
| Edwards, J | 1 |
| Kubota, N | 2 |
| Miyazawa, K | 2 |
| Shoji, N | 2 |
| Sumi, M | 2 |
| Nakajima, A | 2 |
| Kimura, Y | 2 |
| Oshiro, H | 2 |
| Ebihara, Y | 2 |
| Ohyashiki, K | 2 |
| Wu, VC | 1 |
| Wang, R | 1 |
| Lai, TS | 1 |
| Wu, KD | 1 |
| Keijzer, A | 1 |
| van der Valk, P | 1 |
| Ossenkoppele, GJ | 1 |
| van de Loosdrecht, AA | 1 |
| Boelaert, JR | 11 |
| Van Cutsem, J | 3 |
| de Locht, M | 4 |
| Schneider, YJ | 4 |
| Crichton, RR | 1 |
| Olivero, JJ | 1 |
| Kerrels, V | 1 |
| Cantinieaux, B | 1 |
| Verdonck, A | 1 |
| Van Landuyt, HW | 1 |
| Maertens, J | 1 |
| Demuynck, H | 1 |
| Verbeken, EK | 1 |
| Zachée, P | 1 |
| Verhoef, GE | 1 |
| Vandenberghe, P | 1 |
| Boogaerts, MA | 1 |
| Miyata, Y | 1 |
| Kajiguchi, T | 1 |
| Saito, M | 1 |
| Takeyama, H | 1 |
| Barratt, DM | 1 |
| Van Meter, K | 1 |
| Asmar, P | 1 |
| Nolan, T | 1 |
| Trahan, C | 1 |
| Garcia-Covarrubias, L | 1 |
| Metzinger, SE | 1 |
| Verpooten, GA | 1 |
| D'Haese, PC | 1 |
| Becaus, I | 1 |
| Lamberts, LV | 1 |
| De Broe, ME | 1 |
| Seeverens, HJ | 1 |
| Tijhuis, GJ | 1 |
| Ruijs, GJ | 1 |
| Kazzaz, BA | 1 |
| Kauffmann, RH | 1 |
| Ammon, A | 1 |
| Rumpf, KW | 1 |
| Hommerich, CP | 1 |
| Behrens-Baumann, W | 1 |
| Rüchel, R | 1 |
| Anand, VK | 1 |
| Alemar, G | 1 |
| Griswold, JA | 1 |
| Wens, R | 1 |
| Devriendt, J | 1 |
| Collart, F | 1 |
| Dratwa, M | 1 |
| Bisschop, P | 1 |
| Telerman-Toppet, N | 1 |
| Douat, N | 1 |
| Kaneko, T | 1 |
| Abe, F | 2 |
| Ito, M | 1 |
| Hotchi, M | 2 |
| Yamada, K | 1 |
| Okada, Y | 1 |
| Slade, MP | 1 |
| McNab, AA | 1 |
| Fenves, AZ | 3 |
| Coburn, JW | 2 |
| Ponz, E | 1 |
| Campistol, JM | 1 |
| Ribalta, T | 1 |
| Montoliú, J | 1 |
| Ramírez, J | 1 |
| Almirall, J | 1 |
| Revert, L | 1 |
| Vlasveld, LT | 1 |
| van Asbeck, BS | 1 |
| Vandevelde, L | 1 |
| Bondewel, C | 1 |
| Dubois, M | 1 |
| De Vuyst, M | 1 |
| Inaba, H | 1 |
| Katoh, T | 1 |
| Hamdy, NA | 1 |
| Andrew, SM | 1 |
| Shortland, JR | 1 |
| Boletis, J | 1 |
| Raftery, AT | 1 |
| Kanis, JA | 1 |
| Brown, CB | 1 |
| Daly, AL | 1 |
| Velazquez, LA | 1 |
| Bradley, SF | 1 |
| Kauffman, CA | 1 |
| Nakamura, M | 1 |
| Weil, WB | 1 |
| Kaufman, DB | 1 |
| Arizono, K | 1 |
| Fukui, H | 1 |
| Miura, H | 1 |
| Hayano, K | 1 |
| Otsuka, Y | 1 |
| Tajiri, M | 1 |
| Sane, A | 1 |
| Manzi, S | 1 |
| Perfect, J | 1 |
| Herzberg, AJ | 1 |
| Moore, JO | 1 |
| van Roost, GF | 1 |
| Vergauwe, PL | 2 |
| Verbanck, JJ | 1 |
| de Vroey, C | 1 |
| Segaert, MF | 1 |
| Fenves, A | 1 |
| Windus, D | 1 |
| Goodill, JJ | 1 |
| Abuelo, JG | 1 |
| Eiser, AR | 1 |
| Slifkin, RF | 1 |
| Neff, MS | 1 |
| Scheer, RL | 1 |
| Veis, JH | 1 |
| Contiguglia, R | 1 |
| Klein, M | 1 |
| Mishell, J | 1 |
| Alfrey, AC | 1 |
| Shapiro, JI | 1 |
| Windus, DW | 1 |
| Stokes, TJ | 1 |
| Julian, BA | 1 |
| Vandepitte, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study[NCT00419770] | Phase 2 | 20 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00419770)
Timeframe: 30 Days After End of Therapy
| Intervention | Events (Number) |
|---|---|
| Deferasirox | 16 |
| Placebo | 16 |
10 reviews available for deferoxamine and Mucormycosis
| Article | Year |
|---|---|
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbia | 2008 |
Mucormycosis (zygomycosis): is there news for the clinician?
Topics: AIDS-Related Opportunistic Infections; Deferoxamine; Disease Susceptibility; Drug Therapy; Humans; M | 1994 |
[Development of arterial thrombus of Mucorales hyphae during deferoxamine therapy in a patient with aplastic anemia in transformation to myelodysplastic syndrome].
Topics: Anemia, Aplastic; Chelating Agents; Deferoxamine; Fatal Outcome; Female; Humans; Iron Overload; Midd | 2000 |
Dialysis associated mucormycosis and desferrioxamine treatment: a case report with review of the role of oxygen radicals.
Topics: Adult; Deferoxamine; Free Radicals; Humans; Male; Mucormycosis; Reactive Oxygen Species; Renal Dialy | 1992 |
Intracranial complications of mucormycosis: an experimental model and clinical review.
Topics: Adult; Alloxan; Amphotericin B; Animals; Brain Abscess; Brain Diseases; Child; Deferoxamine; Diabete | 1992 |
Intestinal mucormycosis in a hemodialysis patient treated with desferrioxamine.
Topics: Aluminum; Deferoxamine; Female; Humans; Intestinal Diseases; Middle Aged; Mucormycosis; Renal Dialys | 1991 |
Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry.
Topics: Adolescent; Adult; Aged; Deferoxamine; Female; Humans; Male; Middle Aged; Mucormycosis; Registries; | 1991 |
[Disseminated mucormycosis in a hemodialyzed female patient treated with deferoxamine].
Topics: Deferoxamine; Female; Humans; Kidney Failure, Chronic; Middle Aged; Mucormycosis; Renal Dialysis | 1991 |
Mucormycosis: association with deferoxamine therapy.
Topics: Deferoxamine; Drug Overdose; Female; Humans; Iron; Middle Aged; Mucormycosis; Myelodysplastic Syndro | 1989 |
The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
Topics: Adult; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mucormycosis; Renal | 1988 |
1 trial available for deferoxamine and Mucormycosis
| Article | Year |
|---|---|
Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients.
Topics: Adult; Aged; Aluminum; Chelating Agents; Deferoxamine; Ferric Compounds; Hemosiderosis; Humans; Live | 1992 |
31 other studies available for deferoxamine and Mucormycosis
| Article | Year |
|---|---|
Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine.
Topics: Animals; Biological Transport; Deferoxamine; DNA-Binding Proteins; Ferric Compounds; Iron; Iron Chel | 2015 |
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
Topics: Aged; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Deferoxamine; Fatal Outcome; Humans; Male; | 2003 |
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
Topics: Aged; Anemia, Refractory; Deferoxamine; Echocardiography; Fatal Outcome; Heart Diseases; Heart Ventr | 2003 |
Deferoxamine-related fatal nasal-orbital-cerebral mucormycosis.
Topics: Deferoxamine; Facial Bones; Fatal Outcome; Female; Humans; Middle Aged; Mucormycosis; Siderophores | 2006 |
Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Antibodies, Monoclonal; Apoptosis; Combined Modality Ther | 2006 |
Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
Topics: Animals; Deferiprone; Deferoxamine; Guinea Pigs; Iron; Iron Chelating Agents; Male; Mucormycosis; Py | 1994 |
Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus.
Topics: 2,2'-Dipyridyl; Albumins; Cells, Cultured; Deferoxamine; Ferric Compounds; Humans; Iron; Mucormycosi | 1994 |
The effect of deferoxamine on different zygomycetes.
Topics: Deferoxamine; Iron; Mucorales; Mucormycosis; Rhizopus | 1994 |
Hemoptysis and altered sensorium in a hemodialysis patient.
Topics: Aluminum; Aluminum Hydroxide; Brain Diseases; Deferoxamine; Hemoptysis; Humans; Kidney Failure, Chro | 1993 |
Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.
Topics: Animals; Blood Physiological Phenomena; Candida albicans; Candidiasis; Deferoxamine; Guinea Pigs; Hu | 1993 |
Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis.
Topics: Adult; Bone Marrow Transplantation; Deferoxamine; Female; Humans; Iron Overload; Male; Middle Aged; | 1999 |
Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model.
Topics: Amphotericin B; Animals; Antifungal Agents; Combined Modality Therapy; Deferoxamine; Female; Hyperba | 2001 |
[Rhinocerebral mucormycosis during deferoxamine therapy].
Topics: Adult; Blindness; Brain Diseases; Cellulitis; Combined Modality Therapy; Deferoxamine; Female; Human | 1992 |
Rhinocerebral mucormycosis in haemodialysis patients treated with desferrioxamine: possible role of recent surgery as an additional risk factor.
Topics: Amphotericin B; Brain Diseases; Deferoxamine; Humans; Male; Middle Aged; Mucormycosis; Nasal Mucosa; | 1991 |
Fatal mucormycosis therapy associated with deferoxamine.
Topics: Aged; Cellulitis; Deferoxamine; Humans; Male; Mucormycosis; Orbital Diseases | 1991 |
Treatment with deferoxamine: a real risk factor for mucormycosis?
Topics: Aluminum; Deferoxamine; Dialysis; Humans; Injections, Intramuscular; Iron; Male; Middle Aged; Mucorm | 1991 |
Mucorales and deferoxamine: from saprophytic to pathogenic state.
Topics: Deferoxamine; Ethmoid Sinusitis; Humans; Intracranial Embolism and Thrombosis; Male; Middle Aged; Mu | 1990 |
Effects of iron and desferrioxamine on Rhizopus infection.
Topics: Animals; Brain; Deferoxamine; Drug Interactions; Iron; Kidney; Male; Mice; Mice, Inbred ICR; Mucormy | 1990 |
Fatal cardiac zygomycosis in a renal transplant patient treated with desferrioxamine.
Topics: Adult; Deferoxamine; Endomyocardial Fibrosis; Heart Ventricles; Humans; Immunosuppressive Agents; Ki | 1989 |
Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).
Topics: Amphotericin B; Animals; Deferoxamine; Ferric Compounds; Guinea Pigs; Iron; Iron Chelating Agents; M | 1989 |
Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine.
Topics: Adolescent; Deferoxamine; Glomerulonephritis, Membranous; Humans; Kidney Failure, Chronic; Male; Muc | 1989 |
[A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine].
Topics: Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mucormycosis; Rena | 1989 |
Mucormycosis among patients on dialysis.
Topics: Deferoxamine; Humans; Mucormycosis; Renal Dialysis | 1989 |
Deferoxamine treatment as a risk factor for zygomycete infection.
Topics: Aged; Deferoxamine; Humans; Male; Mucormycosis; Opportunistic Infections; Rhizopus; Risk Factors | 1989 |
Uncertainty in clinical decisions.
Topics: Deferoxamine; Humans; Male; Middle Aged; Mucormycosis; Opportunistic Infections | 1988 |
Mucormycosis--a new risk of deferoxamine therapy in dialysis patients with aluminum or iron overload?
Topics: Adult; Aluminum; Deferoxamine; Humans; Iron; Male; Mucormycosis; Renal Dialysis | 1987 |
Intestinal mucormycosis in hemodialysis patients following deferoxamine.
Topics: Deferoxamine; Humans; Intestinal Diseases; Lung Diseases, Fungal; Male; Middle Aged; Mucormycosis; R | 1987 |
Myocardial mucormycosis with emboli in a hemodialysis patient.
Topics: Cardiomyopathies; Deferoxamine; Humans; Mucormycosis; Renal Dialysis | 1987 |
Mucormycosis in deferoxamine-treated patients on dialysis.
Topics: Deferoxamine; Humans; Mucormycosis; Renal Dialysis; Uremia | 1987 |
Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine.
Topics: Adult; Aged; Aluminum; Deferoxamine; Encephalitis; Female; Hemosiderosis; Humans; Male; Middle Aged; | 1987 |
Mucormycosis infection in dialysis patients.
Topics: Deferoxamine; Humans; Iron; Mucormycosis; Renal Dialysis; Yersinia Infections | 1987 |